Multi-modal hydrogel-based platform to deliver and monitor cardiac progenitor/stem cell engraftment
File(s)acscentsci%2E7b00039.pdf (1.77 MB)
Published version
Author(s)
Type
Journal Article
Abstract
Retention and survival of transplanted cells are major limitations to the efficacy of regenerative medicine, with short-term paracrine signals being the principal mechanism underlying current cell therapies for heart repair. Consequently, even improvements in short-term durability may have a potential impact on cardiac cell grafting. We have developed a multimodal hydrogel-based platform comprised of a poly(ethylene glycol) network cross-linked with bioactive peptides functionalized with Gd(III) in order to monitor the localization and retention of the hydrogel in vivo by magnetic resonance imaging. In this study, we have tailored the material for cardiac applications through the inclusion of a heparin-binding peptide (HBP) sequence in the cross-linker design and formulated the gel to display mechanical properties resembling those of cardiac tissue. Luciferase-expressing cardiac stem cells (CSC-Luc2) encapsulated within these gels maintained their metabolic activity for up to 14 days in vitro. Encapsulation in the HBP hydrogels improved CSC-Luc2 retention in the mouse myocardium and hind limbs at 3 days by 6.5- and 12- fold, respectively. Thus, this novel heparin-binding based, Gd(III)-tagged hydrogel and CSC-Luc2 platform system demonstrates a tailored, in vivo detectable theranostic cell delivery system that can be implemented to monitor and assess the transplanted material and cell retention.
Date Issued
2017-03-30
Date Acceptance
2017-03-19
Citation
ACS Central Science, 2017, 3 (4), pp.338-348
ISSN
2374-7951
Publisher
American Chemical Society
Start Page
338
End Page
348
Journal / Book Title
ACS Central Science
Volume
3
Issue
4
Copyright Statement
© 2017 American Chemical Society. This is an open access article published under a Creative Commons Attribution (CC-BY) License, which permits unrestricted use, distribution and reproduction in any medium, provided the author and source are cited.
Sponsor
British Heart Foundation
Medical Research Council (MRC)
British Heart Foundation
British Heart Foundation
Wellcome Trust
British Heart Foundation
Commission of the European Communities
British Heart Foundation
British Heart Foundation
Grant Number
RE/08/002/23906
G0901467
RM/13/1/30157
CH/08/002/25297
098411/Z/12/Z
RE/13/4/30184
ERC-2013-CoG-616417
CH/08/002/25297
RG/15/1/31165
Publication Status
Published